Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Metopimazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.70 |
| ▸ | ADRA2A known ✓ | P08913 | 6/20 | 0.70 |
| ▸ | DRD1 known ✓ | P21728 | 6/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.70 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.70 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.70 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.70 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.59 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.53 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.48 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.48 |
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.48 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metopimazine SCHEMBL22645257 | 0.99 | DRD3 (0.95) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL29462317 | 0.98 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL49905 | 0.98 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL30038347 | 0.98 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL13724685 | 0.92 | DRD3 (0.87) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL24570751 | 0.91 | DRD3 (0.86) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL15857644 | 0.90 | DRD2 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL21473954 | 0.86 | DRD2 (0.79) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL15847810 | 0.86 | DRD2 (0.79) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL30467248 | 0.86 | DRD2 (0.79) | DRD3DRD2HRH1SLC6A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156832-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | NEUROGASTRX, INC. | 2024-05-16 | — | — | US | claimed |
| US-11834445-B2 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2023-12-05 | — | — | US | claimed |
| EP-4271385-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | Neurogastrx, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| US-20230142366-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. | 2023-05-11 | — | — | US | claimed |
| US-20230086867-A1 | POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. | 2023-03-23 | — | — | US | claimed |
| EP-4126831-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | Neurogastrx, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115667234-A | Novel polymorphic forms of metopimazine | 纽洛佳斯特拉斯公司 | 2023-01-31 | — | — | CN | claimed |
| US-11390620-B2 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2022-07-19 | — | — | US | claimed |
| WO-2022146970-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | NEUROGASTRX, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20210323954-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC | 2021-10-21 | — | — | US | claimed |
| WO-2021202839-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. (US) | 2021-10-07 | — | — | WO | claimed |
| US-10836757-B1 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20240156832-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | NEUROGASTRX, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2023234423-A1 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | AMD THERAPEUTICS LLC (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11834445-B2 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834445-B2 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2021202839-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202839-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | NEUROGASTRX, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-10836757-B1 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836757-B1 | Polymorphic forms of metopimazine | NEUROGASTRX, INC. (US) | 2020-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142366-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | CHRNA5, CHRNB3, CHRNB2 | DRD3 1771/4885DRD2 1213/4885SLC6A2 107/4885 |
| US-10836757-B1 | Polymorphic forms of metopimazine | CHRNB3, CHRNB2, CHRNA5 | DRD3 1922/4885DRD2 1254/4885SLC6A2 120/4885 |
| US-20210323954-A1 | NOVEL POLYMORPHIC FORMS OF METOPIMAZINE | CHRNA5, CHRNB3, CHRNB2 | DRD3 1771/4885DRD2 1213/4885SLC6A2 107/4885 |
| US-11834445-B2 | Polymorphic forms of metopimazine | CHRNB3, CHRNB2, CHRNA5 | DRD3 1922/4885DRD2 1254/4885SLC6A2 120/4885 |
| US-20230086867-A1 | POLYMORPHIC FORMS OF METOPIMAZINE | CHRNB3, CHRNB2, CHRNA5 | DRD3 1922/4885DRD2 1254/4885SLC6A2 120/4885 |
| US-11390620-B2 | Polymorphic forms of metopimazine | CHRNB3, CHRNB2, CHRNA5 | DRD3 1922/4885DRD2 1254/4885SLC6A2 120/4885 |
| US-20240156832-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | METAP2, METAP1, SI | DRD3 3279/4885DRD2 2272/4885SLC6A2 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.